ClinicalTrials.gg
Active, not recruitingNCT07465224Updated Nov 13, 2026

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

A Phase 2 interventional study of ALN-4324 and Placebo in Type 2 Diabetes Mellitus (T2DM), sponsored by Alnylam Pharmaceuticals. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Alnylam Pharmaceuticals · Phase 2, Interventional, and Treatment

Updated Nov 13, 2026Now Active, not recruitingStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States — 344 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
2,378th of 2,960
24 · median 90
Started
2026
with 156 others
Phase 2
391 of 3,307
24 open now
Primary completion
2027-05
later than 249 of 477 live
Registered
3,208th of 3,307
by date

Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,378th largest by enrollment of the 2,960 interventional ones that give a count, is one of 157 that started in 2026, is one of 391 in phase 2, reaches primary completion later than 249 of the 477 other live ones, and was the 3,208th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

344 of the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • siRNA
  • RNAi
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is an adult patient with a confirmed diagnosis of T2DM
  • Has a (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
  • Has a (HbA1c) ≥6.5% to \<10.5%
  • Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)

Exclusion criteria

Exclusion Criteria:

  • Has any concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
  • Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or methods

Note: other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ALN-4324

    Participants will be administered a single dose of ALN-4324.

    Drug: ALN-4324

  • Placebo comparator
    Placebo

    Participants will be administered a single dose of placebo.

    Drug: Placebo

Interventions

  • DrugALN-4324

    ALN-4324 will be administered subcutaneously (SC).

  • DrugPlacebo

    Placebo will be administered SC.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in M-value

    M-value is measured as the glucose infusion rate at steady state

    Time frame: Baseline up to Month 3

Secondary outcomes

  1. Frequency of Adverse Events (AEs)

    Time frame: Up to Month 9

  2. Change from Baseline in M/I

    M/I is measured as the ratio of M-value to insulin concentration \[I\] at steady state

    Time frame: Baseline up to Month 6

  3. Change from Baseline in M-value

    M-value is measured as the glucose infusion rate at steady state

    Time frame: Baseline up to Month 6

  4. Change from Baseline in Endogenous Glucose Production (EGP)

    Both in the basal state and during steady state during the hyperinsulinemic euglycemic clamp (HEC) procedure

    Time frame: Baseline up to Month 6

  5. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline up to Month 6

07

Study locations

1 site
  • Clinical Trial Site
    Chula Vista, California 91911, United States
08

References and documents

Individual participant data

Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2027, 16 months after the start.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 16 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

Completion moved once since we started tracking on Sep 25, 2026: May 2027 → Jul 2027, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 11, 2026
StartActual
Jan 15, 2026
Primary completionEst.
May 28, 2027
CompletionEst.
Jul 30, 2027was May 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 13, 2026
Study completion
May 28, 2027→Jul 30, 2027
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Recruiting→Active, not recruiting
    Study completion May 28, 2027→Jul 30, 2027
    + 3 other changes: verification date, contact details and site details
  2. Oct 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07465224
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Jan 15, 2026
Primary completion
May 28, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion